September 2024: 

Loma selected for the Women TechEU Program. 

We are honored to announce that Loma has been selected as a recipient of the Women TechEU grant, a prestigious program by the European Commission that supports female-led deep-tech startups in Europe. This recognition highlights our commitment to pioneering solutions in biotechnology and strengthens our drive to develop a groundbreaking therapeutic vaccine against HPV+ cancers. 

The Women TechEU program is designed to empower women-led companies by providing financial support, mentorship, and access to a unique network of experts and investors across Europe. As part of this program, we will benefit from expert guidance to help accelerate our progress, broaden our market reach, and bring our innovative therapeutic vaccine closer to patients who need it most. 

At Loma, we are passionate about pushing the boundaries of healthcare technology and proud to be part of a program that champions gender diversity in the tech and biotech sectors. With Women TechEU’s support, we are more determined than ever to make strides in our mission to combat HPV-related cancers and improve patient outcomes. 

Stay tuned for updates as we embark on this exciting journey with the Women TechEU program and continue our mission to transform cancer treatment through innovation.